Data investigation

Judged Worse Than Not Losing Weight

Researchers gave 607 people identical descriptions of a stranger, varying only how they had lost weight. The version who used a GLP-1 was judged more harshly than the version who had not lost weight at all.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

Researchers gave 607 people a short description of a stranger and asked what they thought of them. The descriptions were identical except for one detail: how the person had lost weight. The version who had used a GLP-1 was judged more harshly than the version who had dieted, and more harshly than the version who had not lost weight at all.[1]

What was done

The paper reports two randomized experiments. In each, participants read a brief history of a fictional person and then completed measures of weight-related stereotyping and willingness to associate with them. What varied between groups was only the weight history.

Study 1: how the target was described, and how willing participants were to associate with them (N = 607; mean differences on a 1–7 scale).[1]
The person was described as…Result
Having lost weight using a GLP-1Rated most negatively
Having lost weight via diet and exerciseRated better than the GLP-1 target (mean difference 0.52, 95% CI 0.27–0.76)
Not having lost weightAlso rated better than the GLP-1 target (0.26, 95% CI 0.02–0.51)
People were less willing to associate with the person who lost weight on a GLP-1 than with the person who had not lost weight at all.

That last row is the finding. Weight stigma is well documented, and the expectation would be that losing weight reduces it. Here, losing it by this particular route left the person judged worse than if they had not lost it at all.

The second experiment locates it precisely

A second experiment with 706 participants added the situation people fear: regain. Targets were described as having regained weight after stopping a GLP-1, having regained after stopping a diet and exercise plan, never having lost weight, or having maintained a loss.

  • After regain, the GLP-1 and diet-and-exercise targets were judged the same. The extra penalty for the drug disappeared.
  • Both were judged worse than the person who maintained their loss (both P ≤ 0.001).
Put the two studies together and the stigma has a precise shape. The extra penalty does not attach to having taken a drug, because it vanishes once weight returns and both regain groups are judged alike. Regain carries a penalty of its own, the same whichever way the weight was lost. The extra penalty attaches to currently being someone who lost weight with medication, and it is heavier than the stigma of not having lost weight at all.

That is a sharper result than “people are judgmental about these drugs,” and it fits what patients report. Our interview-based coverage found stigma emerging as one of eight themes, varying by what the drug had been prescribed for (see eight things patients said). This is the experimental counterpart, and it puts a direction and a size on something people described from the inside.

What a vignette study can and cannot show

Nobody in these experiments met anyone. Participants read a paragraph about a person who does not exist and rated a description. That measures stated attitudes under conditions designed to isolate one variable, which is why the design can prove that the route to weight loss changes judgments. It is not evidence about how people behave toward actual colleagues, friends or patients.

Stated attitudes and behavior can come apart, so do not read this as a measurement of what you will encounter.

The intervals matter too. Both gaps are in willingness to associate with the person. The gap against the diet-and-exercise target was 0.52 with an interval from 0.27 to 0.76, which is solid. The gap against the no weight loss target, which is the striking one, was 0.26 with an interval from 0.02 to 0.51. That barely excludes zero, on a scale that runs from 1 to 7. It is the most interesting finding here and the least firmly established.

Why it is worth knowing anyway

It names something people are told they are imagining. A patient who senses that disclosing this medication costs them something is not being oversensitive. There is experimental evidence that the disclosure changes how they are evaluated, in the direction they suspect.

It also bears on a practical decision that comes up constantly: whether to tell anyone. There are good clinical reasons to disclose. A medication missing from your record is invisible to interaction checking and to the team preparing a procedure, which we set out in what your doctor cannot see. Those reasons do not disappear because disclosure carries a social cost, and pretending the cost is not there helps nobody.

The authors’ own conclusion is that stigma follows people across the whole cycle of losing and regaining, and that stigma-reduction efforts belong in weight management. That is a reasonable thing to conclude from two experiments with fictional targets, stated at about the right strength.

Frequently Asked Questions

In a randomized vignette experiment with 607 participants, a person described as having lost weight with a GLP-1 was evaluated more negatively than one described as having lost weight through diet and exercise, and more negatively than one described as not having lost weight at all.
The extra penalty disappeared. In a second experiment, targets who regained after stopping a GLP-1 and those who regained after stopping a diet plan were judged the same, and both worse than someone who maintained a loss.
The extra penalty attaches to currently being someone who lost weight with medication. It is not the drug itself, since that penalty vanishes on regain. Regain carries a penalty of its own, but the same one for both regain groups, who were judged alike and both worse than someone who maintained a loss.
It shows that the described route to weight loss changes how a description is rated, which the design proves cleanly. It is not evidence about how people behave toward real individuals, and the most striking comparison had a confidence interval that barely excluded zero.
That is a personal decision, and the clinical reasons to disclose are strong. A medication absent from your record is invisible to interaction checking and to anyone preparing you for a procedure. The social cost appears to be real, and it does not remove the clinical reasons.

References

  1. 1.Standen EC, Phelan SM, Tomiyama AJ. An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation International Journal of Obesity. 2026. PMID: 41933207.

The Mental Health Score That Did Not Move

In the head-to-head trial, physical quality-of-life scores improved clearly over 72 weeks. The Mental Component Summary did not significantly improve in either arm, a result the paper's own conclusion omits.

6 min read

Real, and Below the Threshold

Semaglutide improves patient-reported physical functioning by 1.71 points, with an interval excluding zero. The threshold at which a patient notices a change is 3.7 points. Both are true at once.

6 min read

A Quarter the Odds of Being Offered It

People with diabetes who also have a mental health diagnosis received worse care on almost every measure, and a quarter of the odds of being prescribed a GLP-1, while having half again the odds of being put on insulin.

7 min read

Eight Things Patients Said

Trials measure weight and adverse events. They do not measure being judged for taking a drug. Researchers interviewed 30 people across 15 states and sorted what they said into eight themes.

6 min read

Antipsychotics and Metabolic Harm

The drugs that work best for schizophrenia are the hardest on metabolism, and switching is often not an option. A Danish trial treated the consequence instead, and measured psychiatric symptoms as an outcome.

7 min read

Does Ozempic or Mounjaro Cause Anxiety? What the Trials and Labels Show

In randomized trials, anxiety was no more common on semaglutide or tirzepatide than on placebo. Where cohort studies and adverse-event reports disagree, why low blood sugar and a faster pulse can feel like anxiety, and what is known about panic attacks.

12 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

9.0

YourEra

Semaglutide at $99/month, well below the typical price

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →